백사이트, Inc.
US ˙ NasdaqGS ˙ US92243G1085

SecurityPCVX / Vaxcyte, Inc.
InstitutionJump Financial, LLC
Latest Disclosed Ownership0 shares
Latest Disclosed Value $ 0
Jump Financial, LLC closes position in PCVX / Vaxcyte, Inc.

On May 14, 2026 - Jump Financial, LLC filed a 13F-HR form disclosing ownership of 0 shares of Vaxcyte, Inc. (US:PCVX) valued at $0 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 89,822 shares of Vaxcyte, Inc.. The current value of the position is $0 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-14 2026-03-31 13F Vaxcyte Common Stock 92243G108 0 -100.00 0
2026-02-17 2025-12-31 13F Vaxcyte Common Stock 92243G108 89,822 -101,878 -53.14 4,144 -39.99 0.0443
2025-11-13 2025-09-30 13F Vaxcyte Common Stock 92243G108 191,700 -211,897 -52.50 6,905 -47.37 0.0700
2025-08-13 2025-06-30 13F Vaxcyte Common Stock 92243G108 403,597 303,497 303.19 13,121 247.18 0.1445
2025-05-14 2025-03-31 13F Vaxcyte Common Stock 92243G108 100,100 100,100 3,780 0.0520
2025-02-13 2024-12-31 13F Vaxcyte Common Stock 92243G108 0 -51,516 -100.00 0 -100.00
2024-11-14 2024-09-30 13F Vaxcyte Common Stock 92243G108 51,516 51,516 5,887 0.1200
2024-08-14 2024-06-30 13F VAXCYTE Common Stock 92243G108 0 -30,224 -100.00 0 -100.00
2024-05-13 2024-03-31 13F VAXCYTE Common Stock 92243G108 30,224 30,224 2,065 0.0565
2024-10-21 2023-06-30 13F/A-2 Vaxcyte Common Stock 92243G108 0 -105,800 -100.00 0 -100.00
2024-10-21 2023-06-30 13F/A-1 Vaxcyte Common Stock 92243G108 0 0
2023-08-07 2023-06-30 13F VAXCYTE Common Stock 92243G108 0 -105,800 0
2024-10-21 2023-03-31 13F/A-1 Vaxcyte Common Stock 92243G108 105,800 54,158 104.87 3,965 60.14 0.1649
2023-05-03 2023-03-31 13F VAXCYTE Common Stock 92243G108 105,800 54,158 3,965 0.1649
2023-02-14 2022-12-31 13F VAXCYTE Common Stock 92243G108 51,642 51,642 2,476 0.1312
2021-05-15 2021-03-31 13F VAXCYTE Common Stock 92243G108 0 -8,100 -100.00 0 -100.00
2021-02-12 2020-12-31 13F VAXCYTE Common Stock 92243G108 8,100 8,100 215 0.0366
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.